Le Lézard
Classified in: Health, Science and technology
Subject: Trade Show

BIO KOREA 2024 Opens for Program Registration and Exhibition Applications


BIO KOREA 2024, jointly hosted by the Korea Health Industry Development Institute (KHIDI, President: Cha Soon-do) and Chungcheongbuk-do (Governor: Kim Young-hwan), commenced entry registration and exhibition participating company recruitment from December 4, 2023. The event will be held at COEX in Seoul, Korea from May 8th to 10th, 2024.

BIO KOREA, marking its 19th edition in 2024, has established itself as the preeminent bio-industry event in Korea. For the past 18 years, BIO KOREA has served as a catalyst for business revitalization and technological exchange between domestic and foreign companies, fostering a vibrant ecosystem of innovation and collaboration within the biohealth sector.

Held in May of this year, BIO KOREA 2023 witnessed the participation of approximately 29,400 individuals from 780 companies across 51 countries, resulting in around 1,300 business meetings. Additionally, approximately 330 companies from 18 countries showcased their technologies through approximately 440 exhibition booths. Thematic exhibition halls, such as those dedicated to advanced regenerative medicine, CMO, and CDMO, were operated alongside national halls featuring booths from leading overseas companies from Australia, Canada, Germany, and others, fostering continuous technological and business exchanges among participating companies.

BIO KOREA 2024 will feature exhibitions of domestic and international biohealth companies, as well as a range of programs including business partnering, conferences, and an Invest Fair.

In particular, to provide visitors with a more enriching experience, a special AI hall featuring booths of digital healthcare companies will be operated, along with a docent tour program to assist in visitors' understanding of the participating companies. An unmanned poster exhibition will also be held in the rest area to provide more companies with an opportunity to participate in the exhibition.

Early bird registrations made between December 4, 2023, and February 16, 2024 (Fri.), will receive a 30% discount, while registrations received by April 30, 2024 (Tue.), will receive a 10% discount. On-site registration is also available.

Exhibition Booth Discounts

Applications received by February 16, 2024 (Fri.), will receive a 10% discount on exhibition fees, while applications received by April 5, 2024 (Fri.), will receive a 5% discount. Companies that participated in BIO KOREA 2023 will receive an additional 5% discount.

BIO KOREA 2024 website provides comprehensive information on not only the exhibitions but also various programs, including the new company presentation program, business partnering opportunities, and the Invest Fair.

BIO KOREA entry and exhibition registrations can be conveniently completed on the BIO KOREA website at www.biokorea.org. Participation application inquiry: +82 1661-0810.


These press releases may also interest you

at 22:00
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

at 20:14
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...



News published on and distributed by: